New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 11, 2014
09:21 EDTSRPTRW Baird remains bullish on Sarepta after 144 week DMD data
Baird said Sarepta's 144 week data for eteplirsen did not necessarily help reinforce its NDA filing, but the firm still thinks the drug's ability to delay disease progression is demonstrated by the data. The firm maintains its bullish view of the stock and keeps an Outperform rating and $53 price target on Sarepta.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
15:46 EDTSRPTRick Barry accepts nomination to join Sarepta board
Rick Barry disclosed a 7.66% stake in Sarepta Therapeutics and noted he has been nominated to join the board of the company and has accepted the nomination. No additional purchase or disposition of securities occurred since the last filing of Schedule 13G on February 19, the current filing noted.
May 1, 2015
16:19 EDTSRPTPoint72 Asset reports 5.3% passive stake in Sarepta
07:06 EDTSRPTSarepta announces inducement grants under Nasdaq listing rule 5635(c)(4)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use